|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
198,230,000 |
Market
Cap: |
32.11(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.162 - $0.162 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapies to treat the whole eye. Co.'s gene therapy candidate includes: OCU400, which is used for the treatment of nuclear receptor subfamily 2 group E member 3 mutation-associated retinal diseases and centrosomal protein 290 mutation-associated retinal diseases; OCU410, which is being developed for the treatment of dry age-related macular degeneration (AMD); OCU200, which is designed to treat diabetic macular edema, diabetic retinopathy and wet AMD; and OCU300, which is a small molecule therapeutic in clinical development for patients with ocular graft-versus-host disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
200,278 |
200,278 |
Total Buy Value |
$0 |
$0 |
$99,999 |
$99,999 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
0 |
0 |
0 |
599,809 |
Total Sell Value |
$0 |
$0 |
$0 |
$1,096,737 |
Total People Sold |
0 |
0 |
0 |
3 |
Total Sell Transactions |
0 |
0 |
0 |
8 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Zhang Junge |
Director |
|
2021-11-02 |
4 |
AS |
$15.75 |
$2,357,775 |
I/I |
(149,700) |
881,731 |
|
- |
|
Potti Manish |
Director |
|
2021-11-02 |
4 |
AS |
$15.07 |
$955,875 |
I/I |
(63,429) |
27,695 |
|
- |
|
Castillo Kirsten |
Director |
|
2021-11-02 |
4 |
AS |
$15.00 |
$225,000 |
D/D |
(15,000) |
50,000 |
|
- |
|
Kompella Uday |
Director |
|
2021-11-02 |
4 |
AS |
$16.01 |
$400,250 |
I/I |
(25,000) |
154,416 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2021-11-01 |
4 |
AS |
$14.15 |
$1,632,443 |
D/D |
(115,367) |
406,000 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2021-11-01 |
4 |
OE |
$0.51 |
$58,837 |
D/D |
115,367 |
521,367 |
|
- |
|
Kompella Uday |
Director |
|
2021-11-01 |
4 |
AS |
$14.05 |
$351,250 |
I/I |
(25,000) |
179,416 |
|
- |
|
Subramanian Sanjay |
Chief Financial Officer |
|
2021-10-26 |
4 |
AS |
$11.07 |
$110,700 |
D/D |
(10,000) |
35,591 |
|
- |
|
Kompella Uday |
Director |
|
2021-10-26 |
4 |
AS |
$12.05 |
$301,250 |
I/I |
(25,000) |
204,416 |
|
- |
|
Kompella Uday |
Director |
|
2021-10-25 |
4 |
AS |
$9.08 |
$421,049 |
I/I |
(46,371) |
229,416 |
|
- |
|
Kompella Uday |
Director |
|
2021-10-21 |
4 |
AS |
$9.01 |
$17,101 |
I/I |
(1,898) |
275,787 |
|
- |
|
Kompella Uday |
Director |
|
2021-10-20 |
4 |
AS |
$9.02 |
$15,614 |
I/I |
(1,731) |
277,685 |
|
- |
|
Kumar Ramesh |
Director |
|
2021-10-18 |
4 |
AS |
$8.13 |
$60,975 |
D/D |
(7,500) |
0 |
|
- |
|
Kumar Ramesh |
Director |
|
2021-10-18 |
4 |
OE |
$0.51 |
$3,825 |
D/D |
7,500 |
7,500 |
|
- |
|
Kompella Uday |
Director |
|
2021-10-18 |
4 |
AS |
$8.41 |
$1,682,000 |
I/I |
(200,000) |
279,416 |
|
- |
|
Subramanian Sanjay |
Chief Financial Officer |
|
2021-10-15 |
4 |
AS |
$9.96 |
$79,580 |
D/D |
(7,990) |
45,591 |
|
- |
|
Subramanian Sanjay |
Chief Financial Officer |
|
2021-10-15 |
4 |
OE |
$2.19 |
$17,498 |
D/D |
7,990 |
53,581 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2021-10-15 |
4 |
AS |
$9.80 |
$1,225,000 |
D/D |
(125,000) |
406,000 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2021-10-15 |
4 |
OE |
$0.33 |
$41,250 |
D/D |
125,000 |
531,000 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2021-09-15 |
4 |
AS |
$7.52 |
$940,000 |
D/D |
(125,000) |
406,000 |
|
- |
|
Musunuri Shankar |
Chief Executive Officer |
|
2021-09-15 |
4 |
OE |
$0.33 |
$41,250 |
D/D |
125,000 |
531,000 |
|
- |
|
Subramanian Sanjay |
Chief Financial Officer |
|
2021-08-16 |
4 |
AS |
$7.22 |
$216,600 |
D/D |
(30,000) |
45,591 |
|
- |
|
Subramanian Sanjay |
Chief Financial Officer |
|
2021-08-16 |
4 |
OE |
$0.34 |
$10,200 |
D/D |
30,000 |
75,591 |
|
- |
|
Kompella Uday |
Director |
|
2021-07-30 |
4 |
AS |
$6.81 |
$68,072 |
D/D |
(10,000) |
550,674 |
|
- |
|
Kompella Uday |
Director |
|
2021-07-30 |
4 |
OE |
$1.83 |
$18,300 |
D/D |
10,000 |
560,674 |
|
- |
|
195 Records found
|
|
Page 3 of 8 |
|
|